慢性肾脏病骨骼肌消耗:microRNA的新兴作用
本文综述慢性肾脏病(CKD)中骨骼肌消耗的病理生理机制,重点探讨microRNA(miRNA)在肌肉萎缩发生中的作用。文章还总结了miRNA在肌肉与器官交互对话中的研究进展,以及目前进入临床试验的miRNA靶向治疗。
要点
- CKD骨骼肌消耗表现为肌肉质量、力量和功能丧失,增加并发症和死亡风险。
- miRNA调控肌肉生长、再生和代谢,在CKD肌肉萎缩中表达异常并参与调控。
- miRNA介导肌肉与其他器官的有益交互,可能限制CKD进展。
核心结论
- miRNA在CKD骨骼肌消耗的发生中起重要作用,并参与肌肉与器官间的交互对话,是潜在治疗靶点。
研究设计与样本
- 综述,总结细胞和动物模型及近年CKD中miRNA调控肌肉萎缩的证据。
主要发现
- CKD相关并发症和生活方式激活分解代谢通路、损害肌肉再生,导致蛋白质消耗。
- miRNA异常表达在肌肉萎缩的细胞和动物模型中已被描述,近年证实参与CKD肌肉萎缩调控。
- 新兴证据表明miRNA参与骨骼肌与其他器官的有益交互系统,可能限制CKD进展。
临床怎么用
- 关注miRNA作为CKD骨骼肌消耗的潜在生物标志物和治疗靶点,目前相关药物处于临床试验阶段。
局限性
- CKD骨骼肌消耗的发病机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Skeletal muscle wasting is a common complication of chronic kidney disease (CKD), characterized by the loss of muscle mass, strength and function, which significantly increases the risk of morbidity and mortality in this population. Numerous complications associated with declining renal function and lifestyle activate catabolic pathways and impair muscle regeneration, resulting in substantial protein wasting. Evidence suggests that increasing skeletal muscle mass improves outcomes in CKD, making this a clinically important research focus. Despite extensive research, the pathogenesis of skeletal muscle wasting is not completely understood. It is widely recognized that microRNAs (miRNAs), a family of short non-coding RNAs, are pivotal in the regulation of skeletal muscle homoeostasis, with significant roles in regulating muscle growth, regeneration and metabolism. The abnormal expression of miRNAs in skeletal muscle during disease has been well described in cellular and animal models of muscle atrophy, and in recent years, the involvement of miRNAs in the regulation of muscle atrophy in CKD has been demonstrated. As this exciting field evolves, there is emerging evidence for the involvement of miRNAs in a beneficial crosstalk system between skeletal muscle and other organs that may potentially limit the progression of CKD. In this article, we describe the pathophysiological mechanisms of muscle wasting and explore the contribution of miRNAs to the development of muscle wasting in CKD. We also discuss advances in our understanding of miRNAs in muscle-organ crosstalk and summarize miRNA-based therapeutics currently in clinical trials.
引用
- Robinson KA, Baker LA, Graham-Brown MPM, et al. Skeletal muscle wasting in chronic kidney disease: the emerging role of microRNAs. Nephrol Dial Transplant. 2020. PMID: 31603229. doi:10.1093/ndt/gfz193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。